Endeavour Medtech reports 4.2% stake in Kestra

Endeavour Medtech Growth II LP, Endeavour Medtech Growth II Parallel LP, and Endeavour Medtech II GP Limited report beneficial ownership of 2,448,942 Kestra Medical Technologies common shares, representing 4.20% of the class.

Rhea-AI Filing Summary

Endeavour Medtech Growth II LP, Endeavour Medtech Growth II Parallel LP, and Endeavour Medtech II GP Limited report beneficial ownership of 2,448,942 Kestra Medical Technologies common shares, representing 4.20% of the class.

The filing explains that 2,405,643 shares are held by Endeavour Medtech Growth II LP and 43,299 shares by Endeavour Medtech Growth II Parallel LP, with Endeavour Medtech II GP Limited as general partner for both. All reported shares are subject to shared voting and dispositive power, with no sole voting or dispositive authority. The 4.20% figure is based on 58,349,053 common shares outstanding as of December 5, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake in Kestra Medical Technologies (KMTS) is reported?

The reporting funds disclose beneficial ownership of 2,448,942 Kestra common shares, equal to 4.20% of the class. This percentage is calculated using 58,349,053 shares outstanding as of December 5, 2025, as stated in Kestra’s Form 10-Q.

Which entities are the reporting persons in this Kestra (KMTS) Schedule 13G/A?

The filing is submitted on behalf of Endeavour Medtech Growth II LP, Endeavour Medtech Growth II Parallel LP, and Endeavour Medtech II GP Limited. The general partner, Endeavour Medtech II GP Limited, is identified as managing both limited partnerships that hold the Kestra shares.

How are the 2,448,942 Kestra (KMTS) shares allocated among the Endeavour funds?

Of the total 2,448,942 Kestra common shares, 2,405,643 are held of record by Endeavour Medtech Growth II LP, and 43,299 are held of record by Endeavour Medtech Growth II Parallel LP. The filing notes they may be deemed to share beneficial ownership of all reported shares.

What voting and dispositive powers do the reporting persons have over Kestra (KMTS) shares?

The reporting persons report zero sole voting or dispositive power and shared voting and dispositive power over 2,448,942 Kestra common shares. This means decisions on voting and sale are shared among the reporting entities, rather than controlled individually by any one of them.

Why does the Kestra (KMTS) Schedule 13G/A state ownership is 5 percent or less?

Item 5 confirms the reporting persons’ ownership is 5 percent or less of Kestra’s common shares. With a disclosed 4.20% stake, their holdings fall below the 5% threshold often associated with larger beneficial owners under Section 13 reporting rules.

On what date was the Kestra (KMTS) ownership level measured for this filing?

The ownership percentage is calculated using 58,349,053 Kestra common shares outstanding as of December 5, 2025. The filing date of event is listed as December 31, 2025, tying the disclosure to late-2025 ownership levels.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 04:00 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Kestra Medical Technologies, Ltd.

(Name of Issuer)

Common Shares, par value $1.00 per share

(Title of Class of Securities)

G52441105

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. G52441105

1

Names of Reporting Persons

Endeavour Medtech Growth II LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

GUERNSEY

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,448,942.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,448,942.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,448,942.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.20 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percent of class is calculated based upon 58,349,053 Common Shares outstanding as of December 5, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on December 11, 2025, with the Securities and Exchange Commission (the "Form 10-Q").

SCHEDULE 13G

CUSIP No. G52441105

1

Names of Reporting Persons

Endeavour Medtech Growth II Parallel LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

GUERNSEY

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,448,942.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,448,942.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,448,942.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.20 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percent of class is calculated based upon 58,349,053 Common Shares outstanding as of December 5, 2025, as reported in the Form 10-Q.

SCHEDULE 13G

CUSIP No. G52441105

1

Names of Reporting Persons

Endeavour Medtech II GP Limited

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

GUERNSEY

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,448,942.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,448,942.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,448,942.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.20 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: The percent of class is calculated based upon 58,349,053 Common Shares outstanding as of December 5, 2025, as reported in the Form 10-Q.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Kestra Medical Technologies, Ltd.
(b)	Address of issuer's principal executive offices: 3933 Lake Washington BLVD NE, Suite 200, Kirkland, WA 98003
Item 2.
(a)	Name of person filing: This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"): (i) Endeavour Medtech Growth II LP (ii) Endeavour Medtech Growth II Parallel LP (iii) Endeavour Medtech II GP Limited
(b)	Address or principal business office or, if none, residence: The address and principal business address of each of the Reporting Persons is P.O. Box 656, East Wing Trafalgar Court, Les Banques, St. Peter Port, Guernsey GY1 3PP.
(c)	Citizenship: Endeavour Medtech Growth II LP is a Guernsey limited partnership. Endeavour Medtech Growth II Parallel LP is a Guernsey limited partnership. Endeavour Medtech II GP Limited is a Guernsey company limited by shares.
(d)	Title of class of securities: Common Shares, par value $1.00 per share
(e)	CUSIP No.: G52441105
Item 4.	Ownership
(a)	Amount beneficially owned: 2,405,643 Common Shares are held of record by Endeavour Medtech Growth II LP and 43,299 Common Shares are held of record by Endeavour Medtech Growth II Parallel LP. Endeavour Medtech II GP Limited is the general partner of Endeavour Medtech Growth II LP and Endeavour Medtech Growth II Parallel LP. As a result of foregoing, and the relationships described in Item 2(a) of this Schedule 13G, the Reporting Persons may be deemed to share ownership over the reported 2,448,942 Common Shares, but the filing of this Statement shall not be deemed an admission of such beneficial ownership by any of the Reporting Persons for purposes of Section 13(d) or Section 13(g) or for any other purpose.
(b)	Percent of class: See responses to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See responses to Item 5 on each cover page
	(ii) Shared power to vote or to direct the vote: See responses to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See responses to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See responses to Item 8 on each cover page.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Endeavour Medtech Growth II LP

Signature:	/s/ Nick Barton
Name/Title:	Nick Barton / Director of Endeavour Medtech II GP Limited, its General Partner
Date:	02/17/2026

Endeavour Medtech Growth II Parallel LP

Signature:	/s/ Nick Barton
Name/Title:	Nick Barton / Director of Endeavour Medtech II GP Limited, its General Partner
Date:	02/17/2026

Endeavour Medtech II GP Limited

Signature:	/s/ Nick Barton
Name/Title:	Nick Barton / Director
Date:	02/17/2026

Exhibit Information

Exhibit A Joint Filing Agreement, dated as of May 15, 2025, by and among the Reporting persons and filed with the SEC as Exhibit A to the Schedule 13G filed on such date, is hereby incorporated by reference.